With Eli Lilly's backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party

Kyle Blankenship

With an industrywide pipeline quickly gathering steam, the Chinese oncology market has become a red-hot market for Western investors as well as Big Pharma partners …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With Eli Lilly's backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party

Kyle Blankenship

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Trump 2.0 blog: Wayback Machine is insufficient for US health data, judge says

Travere plans to seek expanded label for kidney drug despite failed trial

Pfizer’s prostate cancer data leak shows promising results in early-stage study

Biohaven lands priority review on second-chance application for neurodegenerative drug

What will pharma's share buyback shopping spree mean for M&A?

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

With Eli Lil­ly's back­ing, a team of Seagen vet­er­ans with ADC chops is look­ing to crash the Chi­nese on­col­o­gy par­ty

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

With Eli Lilly's backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party